PARTICIPANTS of a clinical trial that will determine if the oral antiviral drug molnupiravir can prevent transmission of Covid-19 must be unvaccinated and should have only one Covid positive patient in his household.
The third phase of the trial, announced by Merck and Ridgeback Laboratories who developed the oral antiviral pill, aims to determine if molnupiravir is effective in preventing Covid-19 infection to those who took it as an oral prophylaxis.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.